Skye Bioscience

SKYEPhase 2

Skye Bioscience is pioneering a novel approach to metabolic disease by targeting the peripheral cannabinoid 1 (CB1) receptor, a mechanism previously validated for obesity in Europe but limited by central nervous system side effects. The company's lead asset, nimacimab, is a peripherally-restricted CB1-inhibiting antibody that demonstrated positive Phase 2a combination data with semaglutide, showing additional weight loss without increased gastrointestinal or neuropsychiatric adverse events. Skye is strategically advancing nimacimab through clinical development and exploring partnerships, including a recent collaboration with Halozyme, to position CB1 inhibition as a complementary mechanism in the large and heterogeneous obesity market.

Market Cap

$117.0M

Focus

Small Molecules

SKYE · Stock Price

USD 3.6510.10 (-73.45%)

Historical price data

AI Company Overview

Technology Platform

Platform focused on developing peripherally-restricted inhibitors of the cannabinoid 1 (CB1) receptor, primarily using monoclonal antibody technology, to safely unlock metabolic benefits like increased energy expenditure and fat breakdown while avoiding central nervous system side effects.

Pipeline Snapshot

2 drugs in pipeline

Drug	Indication	Stage
Nimacimab injection + Nimacimab placebo injection + Nimacimab 300 mg injection	Obesity	Phase 2
SBI-100 Ophthalmic Emulsion, 0.5% + SBI-100 Ophthalmic Emulsion, 1.0% + SBI-100 ...	Primary Open Angle Glaucoma	Phase 2

Funding History

Total raised: $50M

PIPE$25MUndisclosedAug 15, 2022

Series B$15MUndisclosedMar 15, 2021

Series A$10MUndisclosedJun 15, 2019

Opportunities

The massive and growing obesity market offers a multi-billion dollar opportunity for complementary mechanisms to GLP-1s.

Nimacimab's peripheral CB1 inhibition could address key limitations of current therapies (e.g., weight regain, muscle loss, GI side effects) and be used in combination to enhance efficacy.

The platform also has potential expansion into other metabolic, inflammatory, and fibrotic diseases.

Risk Factors

Clinical development risk remains high, as the Phase 2a monotherapy arm failed its primary endpoint, requiring successful dose optimization.

The historical safety concerns of CB1 inhibitors create regulatory and market perception hurdles.

Fierce competition from large pharma with deep resources in the obesity space presents a significant commercial challenge.

Competitive Landscape

Skye competes in the obesity market dominated by Novo Nordisk and Eli Lilly's GLP-1/GIP agonists. Its differentiation strategy is based on nimacimab's first-in-class peripheral CB1 antibody mechanism, aiming to offer benefits in body composition, energy expenditure, and tolerability as a complementary or alternative therapy. Other companies are also exploring next-generation obesity mechanisms, including other CB1 inhibitors.